Lubiprostone for Children With Constipation

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >=6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION

Intervention/treatment:
AMITIZA (LUBIPROSTONE)
Medical condition:
CONSTIPATION
Protocol code:
SAG/0211PFC-11S1
Control number:
174079
Status:
Closed
Approved:
May 14, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02138136
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
6 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Team Leader
Organization
Mallinckrodt Pharmaceuticals
Phone:
800-556-3314
Sponsor
SUCAMPO AG

Locations

Sainte Justine University Health Center
Montreal, H3T1C5

Results

See the results from the trial NCT02138136. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?